Benitec Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>BB</div>
BNTC -- USA Stock  

USD 6.40  0.35  5.79%

Benitec Biopharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 4.71 Million. The current year Earnings before Tax is expected to grow to about 5.1 M, whereas Average Assets are forecasted to decline to about 21.7 M. In this post, we will go over Benitec Biopharma. Why are we still confident in hope for a quick recovery. Here I will also go over some basic indicators that the company investors should consider in October.
Published over two weeks ago
View all stories for Benitec Biopharma | View All Stories
Is Benitec Biopharma (NASDAQ:BNTC) finally getting endorsement from investors?
The company is undervalued at 8.45 per share with modest projections ahead. The firm shows a Beta (market volatility) of -0.1456, which signifies not very significant fluctuations relative to the market. Let's try to break down what Benitec's beta means in this case. As returns on the market increase, returns on owning Benitec Biopharma are expected to decrease at a much lower rate. During the bear market, Benitec Biopharma is likely to outperform the market. Even though it is essential to pay attention to Benitec Biopharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Benitec Biopharma Limited exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Benitec Biopharma has an expected return of -0.0353%. Please be advised to confirm Benitec Biopharma sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change to decide if Benitec Biopharma stock performance from the past will be repeated at some point in the near future.

How important is Benitec Biopharma's Liquidity

Benitec Biopharma financial leverage refers to using borrowed capital as a funding source to finance Benitec Biopharma Limited ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Benitec Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Benitec Biopharma's total debt and its cash.

How Benitec utilizes its cash?

To perform a cash flow analysis of Benitec Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Benitec Biopharma is receiving and how much cash it distributes out in a given period. The Benitec Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Benitec Biopharma Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 6.74 Million

What did Benitec Biopharma file with SEC?

The SEC filings are financial statements or other formal documents of Benitec Biopharma Limited that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Benitec shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
View
Other Events
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Benitec shareholders may or may not be submitted as SEC does not always require it.

Detailed Perspective On Benitec Biopharma

The market capitalization of Benitec Biopharma is $2.41 Billion. Almost 89.0 percent of Benitec Biopharma outstanding shares are held by regular investors with 0.48 (percent) owned by insiders and only 10.1 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 2017 2018 2019 2020 (projected)
Revenues USD280 K11.38 M13.09 M14.12 M
Revenues378 K16.16 M18.58 M20.05 M

Ownership Breakdown

Retail Investors
89.42%
Institutions
10.1%
Retail Investors89.42
Insiders0.48
Institutions10.1

Benitec Biopharma has 97 percent chance to finish above $6.54 in October

The coefficient of variation is down to -7126.84 as of today. As of the 4th of September, Benitec Biopharma shows the mean deviation of 3.46, and Risk Adjusted Performance of (0.013489). Benitec Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Benitec Biopharma Limited, which can be compared to its rivals. Please confirm Benitec Biopharma jensen alpha, as well as the relationship between the potential upside and skewness to decide if Benitec Biopharma is priced correctly, providing market reflects its regular price of 6.67 per share. Given that Benitec Biopharma has jensen alpha of (0.06), we suggest you to validate Benitec Biopharma Limited's prevailing market performance to make sure the company can sustain itself at a future point.

The Bottom Line

When is the right time to buy or sell Benitec Biopharma Limited? Buying stocks such as Benitec Biopharma isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. To summarize, as of the 4th of September 2020, our current 30 days Buy-Hold-Sell recommendation on the company is Cautious Hold. We believe Benitec Biopharma is currently undervalued with below average probability of financial unrest for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Benitec Biopharma Limited. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com